[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367440-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-367440-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","a-breast-cancer-pdx-collection-enriched-in-luminal-er-tumors-and-young-premenopausal-patients-invited-commentary","A breast cancer PDX collection enriched in luminal (ER +) tumors and young premenopausal patients - invited commentary","","Breast cancer comprises mammary epithelial neoplasms driven by diverse genetic alterations, producing different treatment responses and clinical outcomes. In practice, estrogen receptor (ER), progesterone receptor (PR), and HER2 expression define luminal A, luminal B, and triple-negative subtypes with distinct biology and therapeutic implications. Around 11% of breast cancers occur in young premenopausal women aged 20–49, where patient-derived xenografts (PDXs) enable integration of personalized medicine with novel agents. A luminal-enriched PDX biobank of 26 lines recapitulates original tumor features and is leveraged to study resistance to CDK4/6 inhibitors, addressing a gap in existing models for these high-risk groups. The work supports deeper insight into tumor biology and treatment responses in understudied populations.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-breast-cancer-pdx-collection-enriched-in-luminal-er-tumors-and-young-premenopausal-patients-invited-commentary/367440/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-breast-cancer-pdx-collection-enriched-in-luminal-er-tumors-and-young-premenopausal-patients-invited-commentary/367440.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":30},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"How are luminal, HER2+, and triple-negative breast cancer subtypes distinguished?","Question",{"text":62,"@type":63},"They are guided by ER, PR, and HER2 expression. This enables classification into luminal A, luminal B, and triple-negative groups with different biological behavior and treatment implications.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"Why are patient-derived xenografts (PDXs) important for this research?",{"text":67,"@type":63},"PDXs provide a powerful way to integrate personalized medicine with novel therapeutic agents and to faithfully recapitulate characteristics of the original tumors.",{"name":69,"@type":60,"acceptedAnswer":70},"What therapeutic strategy does the commentary focus on for advanced luminal breast cancers?",{"text":71,"@type":63},"It highlights the role of CDK4/6 inhibitors (CDK4/6i) alongside endocrine therapy targeting ER to inhibit tumor growth, and emphasizes studying resistance to these inhibitors.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},367440,1790170804,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":30,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":96,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":79,"read_time":143,"preview_page_count":33,"preview_urls":144},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Journal of Pathology  \nJ Pathol June 2025; 266: 125–129  \nPublished online 27 March 2025 in Wiley Online Library (wi[leyonlinelibrary.com](leyonlinelibrary.com) DOI: 10.1002/path.6418)[)](leyonlinelibrary.com) DOI: 10.1002/path.6418)[ DOI:](leyonlinelibrary.com) DOI: 10.1002/path.6418)[ 10.1002/path.6418](leyonlinelibrary.com) DOI: 10.1002/path.6418)  \nINVITED COMMENTARY  \nA breast cancer PDX collection enriched in luminal (ER +) tumorsand young premenopausal patients to identify new therapeutic strategies for high-risk patients†  \nPaola Deﬁlippi 1‡, Francesca Nigrelli 1‡, Pietro Arina2*, Daniela Taverna 1 * and Vincenzo Salemme 1  \n1 Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy  \n2 UCL, Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, UK  \n*Correspondence to: P Arina, Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, Gower Street, London WC1E 6BT, [UK. E-mail:](UK. E-mail: pietro.arina@nhs.net)[ pietro.arina@nhs.net](UK. E-mail: pietro.arina@nhs.net); or D Taverna, Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy. E-mail: daniela.taverna@unito.it  \n†Invited Commentary for Segatto et al. A comprehensive luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitors. J Pathol 2024; 264: 434–447.  \n‡These authors contributed equally to manuscript preparation.  \nAbstract  \nBreast cancer includes a group of neoplasms originating from mammary gland epithelial cells caused by a variety of genetic alterations, with different responses to treatments and outcomes. In clinical practice, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression guides the distinction between luminal A (ER+, PR+, HER2 􀀁 ), luminal B (ER+, PR+, HER2+/􀀁), and triple-negative (ER 􀀁 , PR 􀀁 , HER2 􀀁 ), each with a distinct biological behavior and clinical and therapeutic implications. Approximately 11% of breast cancers are diagnosed in young premenopausal women aged 20–49 years. Patient-derived xenografts (PDXs) offer a powerful solution to integrate personalized medicine and novel therapeutic agents. Dr Belletti’s group recently developed a PDX biobank composed of 26 PDX lines highly enriched in luminal A and B and young premenopausal breast cancer patients. The bank faithfully recapitulates the characteristics of the original tumors. A major focus of their research was to exploit these PDXs to assess the resistance to CDK4/6 inhibitors (CDK4/6i), which are critical in managing advanced luminal breast cancers. Their effort addresses a signiﬁcant gap in existing PDX models, which are limited for these patient subgroups, thereby enabling deeper insights into tumor biology and therapeutic responses in these understudied populations.  \n© 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great  \nBritain and Ireland.  \nKeywords: breast cancer; PDX; CDK4/6 inhibitors  \nReceived 4 February 2025; Accepted 24 February 2025  \nNo conﬂicts of interest were declared.  \nBreast cancer classiﬁcation and response to therapy  \nBreast cancer (BC) is the second leading cause of cancer death among women overall [1] . Luminal BC (LBC), which accounts for roughly 70% of BC cases [2], is further classiﬁed into two subtypes: LBC A: ER+/PR+, low proliferation, and generally HER2 􀀁 ; and LBCB: ER+/PR+, higher proliferation, with some HER2+ cases. The HER2+ subtype, derived from the ampliﬁcation of the HER2 oncogene, comprises 15–20% of all BCs; the remaining 15–20% represents triple-negative (TN) BC, which lacks ER, PR, and HER2 . Moreover, premenopausal patients under 40 years of age likely present with more aggressive disease subtypes, such as TNBC ","cbCaitcz7BBEKKce","https://ap.wps.com/l/cbCaitcz7BBEKKce","pdf",1922349,"English","# Breast cancer classiﬁcation and response to therapy\n## Luminal, HER2+, and triple-negative subtypes\n## Therapy approaches: targeted therapy and endocrine treatment\n## CDK4/6 inhibitors and resistance mechanisms","[{\"question\":\"How are luminal, HER2+, and triple-negative breast cancer subtypes distinguished?\",\"answer\":\"They are guided by ER, PR, and HER2 expression. This enables classification into luminal A, luminal B, and triple-negative groups with different biological behavior and treatment implications.\"},{\"question\":\"Why are patient-derived xenografts (PDXs) important for this research?\",\"answer\":\"PDXs provide a powerful way to integrate personalized medicine with novel therapeutic agents and to faithfully recapitulate characteristics of the original tumors.\"},{\"question\":\"What therapeutic strategy does the commentary focus on for advanced luminal breast cancers?\",\"answer\":\"It highlights the role of CDK4/6 inhibitors (CDK4/6i) alongside endocrine therapy targeting ER to inhibit tumor growth, and emphasizes studying resistance to these inhibitors.\"}]","A breast cancer PDX collection enriched in luminal (ER +) tumors and young premenopausal patients - invited commentary | PDF",13,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49be5b0c238dea6ff327c363eaee4869.webp",983,1390,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/020b1c8b1ac251aff3fc07525c28d446.webp",982,1388,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5045d0b89bdb760f83803c317965976a.webp",981,1387,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f4b026951cf1b3789abffc03315d16b.webp",980,1385]